Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

Needham sees no near-term catalysts for Biogen The brokerage said it sees Leqembi’s sales projection “likely to continue to be a slow grind, rather than see an inflection point” and said it ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean firm just agreed to buy Biogen out of their ...

Sage to abandon development of neurological disorder drug after multiple failures November 20, 2024 The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's ...

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this ...

In the past we had organized tours in Novartis and Novozymes. This year, the tour was conducted on 23 rd January at the Biogen Idec 2,000L and 15,000L manufacturing facilities. Biogen Idec is a ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Biogen Pharmachem Industries Limited is an India-based company, which is not engaged in any activity. The Company is looking for the right opportunity to make the Company operational. What is the ...

This has been accurately measured by us with a professional measuring wheel. The course is in Braywick Park, Maidenhead. The course is run on a mixture of hard trail paths and loose gravel. Some ...